IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY

被引:0
|
作者
Cramer, P.
Chanan-Khan, A. [1 ]
Demirkan, F. [2 ]
Fraser, G. [3 ]
Santucci Silva, R. [4 ]
Pylypenko, H. [5 ]
Grosicki, S. [6 ]
Janssens, A. [7 ]
Pristupa, A. [8 ]
Mayer, J. [9 ]
Dilhuydy, M. S. [10 ]
Loscertales, J. [11 ]
Bartlett, N. L. [12 ]
Avigdor, A. [13 ,14 ]
Rule, S. [15 ]
Sun, S. [16 ]
Mahler, M. [16 ]
Salman, M. [16 ]
Howes, A. [17 ]
Hallek, M. [18 ,19 ]
机构
[1] Mayo Clin, IL-52621 Jacksonville, FL USA
[2] Dokuz Eylul Univ, Juravinski Canc Ctr, IL-69978 Izmir, Turkey
[3] McMaster Univ, Hemomed Oncol & Hematol, Hamilton PL6 8DH, ON, Canada
[4] IEP SAO LUCAS, Dept Hematol, Sao Paulo, Brazil
[5] Cherkassy Reg Oncol Ctr, Fac Publ Hlth, Dept Canc Prevent, Cherkassy, Ukraine
[6] Silesian Med Univ, D-50931 Katowice, Poland
[7] Univ Ziekenhuizen Leuven, D-50931 Leuven, Belgium
[8] Reg Clin Hosp, Dept Internal Med Hematol & Oncol, Ryazan, Russia
[9] Univ Hosp Brno, Brno, Czech Republic
[10] Hop Haut Leveque, Hematol Dept, IIS IP, Pessac, France
[11] Hosp Univ La Princesa, Sch Med, Siteman Canc Ctr, Madrid, Spain
[12] Washington Univ, Div Hematol & Bone Marrow Transplantat, St Louis, MO USA
[13] Chaim Sheba Med Ctr, Sackler Sch Med, Tel Hashomer, Israel
[14] Tel Aviv Univ, Dept Haematol, Tel Aviv, Israel
[15] Derriford Hosp, Plymouth, Devon, England
[16] Janssen Res & Dev LLC, Raritan, NJ USA
[17] Janssen Res & Dev, Dept Internal Med 1, High Wycombe, Bucks, England
[18] Univ Cologne, Ctr Integrated Oncol, Cologne, Germany
[19] Univ Cologne, Cologne, Germany
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
LB218
引用
收藏
页码:55 / 56
页数:2
相关论文
共 50 条
  • [41] A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL)
    Shouse, Geoffrey
    Chen, Lu
    Siddiqi, Tanya
    Muir, Alex
    Brown, Jennifer
    Spurgeon, Stephen
    Danilov, Alexey
    LEUKEMIA & LYMPHOMA, 2023, 64 : S105 - S106
  • [42] Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
    Byrd, John C.
    Hillmen, Peter
    Ghia, Paolo
    Kater, Arnon P.
    Chanan-Khan, Asher
    Furman, Richard R.
    O'Brien, Susan
    Yenerel, Mustafa Nuri
    Illes, Arpad
    Kay, Neil
    Garcia-Marco, Jose A.
    Mato, Anthony
    Pinilla-Ibarz, Javier
    Seymour, John F.
    Lepretre, Stephane
    Stilgenbauer, Stephan
    Robak, Tadeusz
    Rothbaum, Wayne
    Izumi, Raquel
    Hamdy, Ahmed
    Patel, Priti
    Higgins, Kara
    Sohoni, Sophia
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) : 3441 - +
  • [43] A Phase II Study of Intermittent Duvelisib Dosing in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Shouse, Geoffrey P.
    Chen, Lu
    Siddiqi, Tanya
    Muir, Alex
    Brown, Jennifer R.
    Spurgeon, Stephen E.
    Danilov, Alexey
    BLOOD, 2023, 142
  • [46] Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    Coutre, Steven
    Byrd, John C.
    Hillmen, Peter
    Barrientos, Jacqueline C.
    Barr, Paul M.
    Devereux, Stephen
    Robak, Tadeusz
    Kipps, Thomas J.
    Schuh, Anna
    Moreno, Carol
    Furman, Richard R.
    Burger, Jan
    O'Dwyer, Michael
    Ghia, Paolo
    Valentino, Rudolph
    Suzuki, Samuel
    Ninomoto, Joi
    James, Danelle F.
    O'Brien, Susan M.
    BLOOD, 2016, 128 (22)
  • [47] Phase I/II study of thrice weekly rituximab in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): A feasible and active regimen.
    Byrd, JC
    Grever, MR
    Davis, B
    Lucas, MS
    Park, K
    Goodrich, A
    Morrison, C
    Murphy, T
    Kunkel, L
    Grillo-Lopez, A
    Waselenko, JK
    Flinn, IW
    BLOOD, 1999, 94 (10) : 704A - 705A
  • [48] A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
    William, Basem M.
    Brillhart, Kaylee
    Afable, Manuel
    Bakalarz, Kristen
    Cooper, Brenda
    Lazarus, Hillard M.
    Gerson, Stanton L.
    Creger, Richard
    Nagabhushanam, Kalyanam
    Grote, James
    Fu, Pingfu
    Kunati, Sandeep
    Yang, Shuming
    Xu, Yan
    Woost, Philip
    Jacobberger, James
    de Lima, Marcos
    Caimi, Paolo
    BLOOD, 2018, 132
  • [49] Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Kipps, Thomas J.
    Fraser, Graeme
    Coutre, Steven
    Brown, Jennifer R.
    Barrientos, Jacqueline C.
    Barr, Paul M.
    Byrd, John C.
    O'Brien, Susan M.
    Dilhuydy, Marie-Sarah
    Devereux, Stephen
    Jaeger, Ulrich
    Moreno, Carol
    Cramer, Paula
    Stilgenbauer, Stephan
    Chanan-Khan, Asher A.
    Mahler, Michelle
    Salman, Mariya
    Cheng, Mei
    Londhe, Anil
    Ninomoto, Joi
    Howes, Angela
    James, Danelle
    Hallek, Michael
    CANCER RESEARCH, 2017, 77
  • [50] Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.
    Barr, Paul M.
    Munir, Talha
    Brown, Jennifer R.
    O'Brien, Susan Mary
    Barrientos, Jacqueline Claudia
    Reddy, Nishitha M.
    Coutre, Steven
    Tam, Constantine Si Lun
    Mulligan, Stephen P.
    Jager, Ulrich
    Kipps, Thomas J.
    Moreno, Carol
    Montillo, Marco
    Burger, Jan Andreas
    Byrd, John C.
    Hillmen, Peter
    Dai, Sandra
    Szoke, Anita
    Dean, James P.
    Woyach, Jennifer Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)